Literature DB >> 11745409

Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice.

M Hardwick1, J Rone, Z Han, B Haddad, V Papadopoulos.   

Abstract

MDA-MB-231 (MDA-231) human breast cancer cells have a high proliferation rate, lack the estrogen receptor, express the intermediate filament vimentin, the hyaluronan receptor CD44, and are able to form tumors in nude mice. The MDA-231 cell line has been used in our laboratory to examine the role of the peripheral-type benzodiazepine receptor (PBR) in the progression of cancer. During these studies 2 populations of MDA-231 cells were subcloned based on the levels of PBR. The subclones proliferated at approximately the same rate, lacked the estrogen receptor, expressed vimentin and CD44, and had the same in vitro chemoinvasive and chemotactic potential. Both restriction fragment length polymorphism and comparative genomic hybridization analyses of genomic DNA from these cells indicated that both subclones are of the same genetic lineage. Only the subclone with high PBR levels, however, was able to form tumors when injected in SCID mice. These data suggest that the ability of MDA-231 cells to form tumors in vivo may depend on the amount of PBR present in the cells. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745409     DOI: 10.1002/ijc.1472

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

2.  Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer.

Authors:  Shelby K Wyatt; H Charles Manning; Mingfeng Bai; Stephanie N Bailey; Pascal Gallant; Guobin Ma; Laura McIntosh; Darryl J Bornhop
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

3.  Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma.

Authors:  Dewei Tang; Michael L Nickels; M Noor Tantawy; Jason R Buck; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

4.  Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide.

Authors:  Dewei Tang; Matthew R Hight; Eliot T McKinley; Allie Fu; Jason R Buck; R Adam Smith; Mohammed Noor Tantawy; Todd E Peterson; Daniel C Colvin; M Sib Ansari; Michael Nickels; H Charles Manning
Journal:  J Nucl Med       Date:  2012-01-17       Impact factor: 10.057

5.  A unified structural model of the mammalian translocator protein (TSPO).

Authors:  Yan Xia; Kaitlyn Ledwitch; Georg Kuenze; Amanda Duran; Jun Li; Charles R Sanders; Charles Manning; Jens Meiler
Journal:  J Biomol NMR       Date:  2019-06-26       Impact factor: 2.835

6.  A non-intrusive evaluation method for tumor-targeting characteristics of nanomedicines based on in vivo near-infrared fluorescence imaging.

Authors:  Hao Liu; Rebecca T Marquez; Xiaoqing Wu; Ke Li; Shweta Vadlamani; Song Li; Ya Wang; Liang Xu; Daocheng Wu
Journal:  J Mater Chem B       Date:  2019-08-07       Impact factor: 6.331

7.  Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma.

Authors:  Dewei Tang; Jun Li; Michael L Nickels; Gang Huang; Allison S Cohen; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

8.  Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells.

Authors:  Luisella Righi; Silvia Deaglio; Carla Pecchioni; Armando Gregorini; Alberto L Horenstein; Gianni Bussolati; Anna Sapino; Fabio Malavasi
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

9.  Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.

Authors:  C Cellai; A Laurenzana; A M Vannucchi; R Caporale; M Paglierani; S Di Lollo; A Pancrazzi; F Paoletti
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

10.  Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab.

Authors:  Aniello DE Rosa; Silvia Zappavigna; Maria Rosaria Villa; Salvatore Improta; Elena Cesario; Lucia Mastrullo; Michele Caraglia; Paola Stiuso
Journal:  Oncol Lett       Date:  2014-12-19       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.